Implementation Structure and Active Task Forces
The Drug Evaluation Committee has established Special Subcommittees and topic-specific Task Forces to solve various issues in drug development with the mission of "delivering innovative and highly useful drugs to patients, medical professionals and people around the world as quickly as possible.
Please refer to the following documents to see the Scope of the Specialized Task Forces and the list of active Task Forces.
-
Drug Evaluation Committee
The committee oversees the subcommittees and committee task forces under the committee, examines technologies and regulations in drug development, makes policy recommendations, and conducts educational activities.
-
List of Task Forces
See a list of active Task Forces under the Committee.
-
Basic Research Subcommittee
The committee examines technologies and regulations related to basic research (non-clinical) in drug development, makes policy recommendations, and conducts educational activities.
-
Clinical Evaluation Subcommittee
The committee examines technologies and regulations related to drug development, from development planning and clinical trial implementation to regulatory approval application and post-marketing activities, and makes policy recommendations and conducts educational activities.
-
Pharmacovigilance Subcommittee
The committee examines technologies and regulations related to pharmacovigilance of pharmaceutical products, makes policy recommendations, and conducts educational activities.
-
Data Science Subcommittee
The committee examines technologies and regulations related to data science from drug development to post-marketing, makes policy recommendations, and conducts educational activities.
-
Electronic Information Subcommittee
The committee examines standardization, technology, and regulations related to electronic information in drug development, and makes policy recommendations and conducts educational activities.
-
Medical Affairs Subcommittee
Examines technologies and regulations related to medical affairs activities, makes policy recommendations, and conducts educational activities.
-
Medical Information DB Utilization Promotion TF
The committee examines technologies, regulations, etc. related to the utilization of medical information data, etc. across the various committees of the Pharmaceutical Manufacturers Association of Japan (PMAJ), and makes policy recommendations and conducts awareness-raising activities.
-
DX study TF
The committee examines various aspects of digital transformation in drug development, makes policy recommendations, and conducts educational activities.
-
GCP renovation/ Clinical trial and clinical research ecosystem study TF
The committee examines and disseminates various measures to improve the environment for clinical trials and clinical research and to promote the implementation of ICH-E6 (R3) in Japan.
